Patents by Inventor Michel Faure
Michel Faure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160053121Abstract: The invention relates to a plasterboard comprising a layer of plaster and at least one facing arranged on the latter, the facing being coated with a coating slip comprising a microporous material, said microporous material comprising agglomerates of precipitated silica. The invention also relates to a coating slip, a facing, and methods of manufacture for supplying said plasterboard.Type: ApplicationFiled: March 23, 2014Publication date: February 25, 2016Applicant: SINIAT INTERNATIONAL SASInventors: Göran HEDMAN, Jean-Michel FAURE
-
Patent number: 8962713Abstract: A method includes using copolymers including at least polyoxyalkylenated monomer units and at least phosphorus-comprising monomer units as water-reducing agent in hydraulic binders.Type: GrantFiled: March 23, 2010Date of Patent: February 24, 2015Assignee: Continental Building Products LLCInventors: Jean-Michel Faure, Olivier Watt, David Rinaldi, Hakimi Yahiaoui
-
Patent number: 8729160Abstract: A method includes adding at least one copolymer or a salt thereof acting as a plasticizer, blocking agent, or both a plasticizer and a blocking agent, to a calcium sulphate-based hydraulic binder. The copolymer includes an acrylic acid or a poly(oxy)alkylene copolymer.Type: GrantFiled: December 12, 2008Date of Patent: May 20, 2014Assignee: Lafarge SAInventors: Jean-Michel Faure, David Rinaldi, Horacio Naranjo
-
Patent number: 8664256Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.Type: GrantFiled: July 11, 2012Date of Patent: March 4, 2014Assignee: Novartis AGInventors: Tinya Abrams, Paul A. Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
-
Publication number: 20140005070Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) markers in a patient treated with a Cyclin Dependent Kinase Inhibitor (CDKI), methods of determining the sensitivity of a cell to a CDKI by measuring PD markers and methods of screening for candidate CKDI.Type: ApplicationFiled: March 28, 2012Publication date: January 2, 2014Applicant: Novartis AGInventors: Michel Faure, Zhenhai Gao, James Sutton, Guoying Karen Yu
-
Patent number: 8552093Abstract: A method of using an admixture in hydraulic binders, in particular in plaster-based or anhydrous calcium sulphate-based compounds, the admixture being an acrylic polymer with controlled end chains.Type: GrantFiled: June 10, 2009Date of Patent: October 8, 2013Assignee: Lafarge Gypsum InternationalInventors: Laurent Meunier, David Rinaldi, Hakimi Yahiaoui, Jean-Michel Faure
-
Publication number: 20130237546Abstract: The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma, inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.Type: ApplicationFiled: October 4, 2012Publication date: September 12, 2013Applicant: Novartis AGInventors: Nguyen Tan, Eleni Venetsanakos, Michel Faure, Carla Heise
-
Publication number: 20130012560Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.Type: ApplicationFiled: July 11, 2012Publication date: January 10, 2013Inventors: Tinya Abrams, Paul Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
-
Patent number: 8288087Abstract: The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.Type: GrantFiled: July 26, 2007Date of Patent: October 16, 2012Assignee: Novartis AGInventors: Nguyen Tan, Eleni Venetsanakos, Michel Faure, Carla Heise
-
Patent number: 8252832Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.Type: GrantFiled: November 25, 2008Date of Patent: August 28, 2012Assignee: Novartis AGInventors: Tinya Abrams, Paul Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
-
Patent number: 8227537Abstract: A finishing compound having acoustic properties and including in percentage by weight relative to the total weight of the product, at least 25 to 80% of water; 0.1 to 5% of a thickening agent; 0.01 to 0.8% of a dispersing agent; 10 to 60% of a monogranular filler wherein the D50 is greater than or equal to 100 ?m; 0.5 to 6% of binder; and not including a foaming agent; and presenting permeability to air after evaporation of the water from 800 to 6000 mks Rayls.Type: GrantFiled: April 21, 2009Date of Patent: July 24, 2012Assignee: Lafarge Gypsum InternationalInventors: Florence Serre, Rita Faddoul, Jean-Michel Faure, Claude Stock
-
Patent number: 8193262Abstract: A finishing compound having acoustic properties and including in percentage by weight relative to the total weight of the product, at least 10 to 70% of water; 0.1 to 5% of a foaming agent; 0.1 to 5% of a thickening agent; 35 to 70% of a monogranular filler having a size greater than or equal to 100 ?m and excluding fine fillers; 0.1 to 8% of synthetic or animal fibers; 0.5 to 35% of binder.Type: GrantFiled: April 21, 2009Date of Patent: June 5, 2012Assignee: Lafarge Gypsum InternationalInventors: Florence Serre, Rita Faddoul, Jean-Michel Faure, Claude Stock
-
Publication number: 20120016059Abstract: A method includes using copolymers including at least polyoxyalkylenated monomer units and at least phosphorus-comprising monomer units as water-reducing agent in hydraulic binders.Type: ApplicationFiled: March 23, 2010Publication date: January 19, 2012Applicant: LAFARGE GYPSUM INTERNATIONALInventors: Jean-Michel Faure, Olivier Watt, David Rinaldi, Hakimi Yahiaoui
-
Publication number: 20110086947Abstract: A method of using an admixture in hydraulic binders, in particular in plaster-based or anhydrous calcium sulphate-based compounds, the admixture being an acrylic polymer with controlled end chains.Type: ApplicationFiled: June 10, 2009Publication date: April 14, 2011Applicant: LAFARGE GYPSUM INTERNATIONALInventors: Laurent Meunier, David Rinaldi, Hakimi Yahiaoui, Jean-Michel Faure
-
Publication number: 20110042163Abstract: A finishing compound having acoustic properties and including iii percentage by weight relative to the total weight of the product, at least 10 to 70% of water; 0.1 to 5% of a foaming agent; 0.1 to 5% of a thickening agent; 35 to 70% of a monogranular filler having a size greater than or equal to 100 ?m and excluding fine fillers; 0.1 to 8% of synthetic or animal fibres; 0.5 to 35% of binder.Type: ApplicationFiled: April 21, 2009Publication date: February 24, 2011Applicant: Lafarge Gypsum InternationalInventors: Florence Serre, Rita Faddoul, Jean-Michel Faure, Claude Stock
-
Publication number: 20110034608Abstract: A finishing compound having acoustic properties and including in percentage by weight relative to the total weight of the product, at least 25 to 80% of water; 0.1 to 5% of a thickening agent; 0.01 to 0.8% of a dispersing agent; 10 to 60% of a monogranular filler wherein the D50 is greater than or equal to 100 ?m; 0.5 to 6% of binder; and not including a foaming agent; and presenting permeability to air after evaporation of the water from 800 to 6000 mks Rayls.Type: ApplicationFiled: April 21, 2009Publication date: February 10, 2011Applicant: LAFARGE GYPSUM INTERNATIONALInventors: Florence Serre, Rita Faddoul, Jean-Michel Faure, Claude Stock
-
Publication number: 20100273916Abstract: A method includes adding at least one copolymer or a salt thereof acting as a plasticizer, blocking agent, or both a plasticizer and a blocking agent, to a calcium sulphate-based hydraulic binder. The copolymer includes an acrylic acid or a poly(oxy)alkylene copolymer.Type: ApplicationFiled: December 12, 2008Publication date: October 28, 2010Applicant: Lafarge PlatresInventors: Jean-Michel Faure, David Rinaldi, Horacio Naranjo
-
Publication number: 20100009392Abstract: The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.Type: ApplicationFiled: July 26, 2007Publication date: January 14, 2010Inventors: Nguyen Tan, Eleni Venetsanakos, Michel Faure, Carla Heise
-
Publication number: 20090301354Abstract: A method of compressing a composition includes compacting a hydraulic binder in a quantity greater than 95% by weight and a disintegrating agent in a quantity less than or equal to 0.5% by weight, into compacts in a roller press. The milled pellet of a composition including a hydraulic binder in a quantity greater than 95% by weight and a disintegrating agent in a quantity less than or equal to 0.5% by weight.Type: ApplicationFiled: April 14, 2006Publication date: December 10, 2009Inventors: Jean-Michel Faure, Corinne Fonquerne, Emmanuel Garcia
-
Publication number: 20090239922Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.Type: ApplicationFiled: November 25, 2008Publication date: September 24, 2009Inventors: Tinya Abrams, Paul Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter